Production (Stage)
Ligand Pharmaceuticals Incorporated
LGND
$105.99
$1.811.74%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 181.49M | 167.13M | 152.42M | 133.48M | 118.31M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 181.49M | 167.13M | 152.42M | 133.48M | 118.31M |
| Cost of Revenue | 78.58M | 32.50M | 32.37M | 33.26M | 33.52M |
| Gross Profit | 102.91M | 134.63M | 120.06M | 100.22M | 84.79M |
| SG&A Expenses | 86.50M | 78.65M | 69.04M | 59.22M | 52.89M |
| Depreciation & Amortization | 33.03M | 32.96M | 33.04M | 33.02M | 33.30M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 198.11M | 144.11M | 134.45M | 125.50M | 119.71M |
| Operating Income | -16.63M | 23.02M | 17.98M | 7.98M | -1.40M |
| Income Before Tax | -161.11M | 2.52M | 58.82M | 53.01M | 121.57M |
| Income Tax Expenses | -28.49M | 6.55M | 13.57M | 10.87M | 25.23M |
| Earnings from Continuing Operations | -132.62 | -4.03 | 45.24 | 42.14 | 96.34 |
| Earnings from Discontinued Operations | -- | -- | 0.00 | 0.00 | 0.00 |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -132.62M | -4.03M | 45.24M | 42.14M | 96.34M |
| EBIT | -16.63M | 23.02M | 17.98M | 7.98M | -1.40M |
| EBITDA | 18.16M | 58.26M | 53.50M | 43.94M | 34.77M |
| EPS Basic | -7.12 | -0.05 | 2.63 | 2.43 | 5.44 |
| Normalized Basic EPS | -1.90 | -0.58 | -0.99 | -0.73 | 0.10 |
| EPS Diluted | -7.12 | -0.16 | 2.51 | 2.31 | 5.32 |
| Normalized Diluted EPS | -1.90 | -0.58 | -0.99 | -0.73 | 0.10 |
| Average Basic Shares Outstanding | 74.61M | 73.15M | 71.65M | 70.61M | 69.85M |
| Average Diluted Shares Outstanding | 74.61M | 73.54M | 72.25M | 71.21M | 70.91M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |